Industries > Pharma > Controlled Substance Market Report 2021-2031
Controlled Substance Market Report 2021-2031
Forecasts by Drug (Opioids, Stimulants, Depressants, and Cannabinoids), by Application (Attention-Deficit/Hyperactivity Disorder (ADHD), Pain Management, Depression, Sleep Disorder, Cough Suppression, Anxiety, Seizure, and Others), by Drug Type (Generic Drugs, and Branded Drugs), by Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), by End User (Hospitals, Homecare, Specialty Clinics, and Others), by Distribution Channel (Institutional Sale, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios
Controlled Substance Market– our new study reveals trends, R&D progress, and predicted revenues
Where the Controlled Substance is market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2031, assessing data, trends, opportunities, and business prospects there.
Discover how to stay ahead
Our 250+ page report provides 420+ tables and 400+ charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Controlled Substance Market. See how to exploit the opportunities.
Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market By Drug
• Opioids
o Codeine
o Morphine
o Fentanyl
o Hydrocodone
o Tramadol
o Oxycodone
o Others
• Stimulants
o Amphetamine
o Methylphenidate
o Dextroamphetamine
o Methamphetamine
o Modafinil
o Others
• Depressants
o Barbiturates
o Benzodiazepines
• Cannabinoids
o Medical
o Recreational
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market By Application
• Attention-Deficit/Hyperactivity Disorder (ADHD)
• Pain Management
• Depression
• Sleep Disorder
• Cough Suppression
• Anxiety
• Seizure
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market By Drug Type
• Generic Drugs
• Branded Drugs
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market By Patient Demographics
• Geriatric Patient
• Adult Patient
• Pediatric
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market by End User
• Hospitals
• Homecare
• Specialty Clinics
• Others
• Revenue and growth forecasts from 2021 to 2031 for the Global Controlled Substance Market by Distribution Channel
• Institutional Sale
o Clinics
o Hospital Pharmacies
o Others
• Retail Sales
o Retail Pharmacies
o E- Commerce/Mail Order Pharmacies
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 20 leading national markets:
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o United Kingdom
o Italy
o Spain
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Argentina
o Rest of Latin America
• Middle East and Africa
o Turkey
o Saudi Arabia
o South Africa
o UAE
o Egypt
o Rest of Middle East and Africa
The report also includes profiles and for some of the leading companies in the Controlled Substance Market, with a focus on this segment of these companies’ operations.
Leading companies and the potential for market growth
Overall world revenue for Controlled Substance Market will surpass $xx million in 2021, our work calculates. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the Controlled Substance Market report helps you
In summary, our 500+ page report provides you with the following knowledge:
• Revenue forecasts to 2031 for Controlled Substance Market, with forecasts for Get our report today Controlled Substance Market Forecast 2021-2031: By Drug, Application, Drug Type, Patient Demographics, End User, Distribution Channel and Leading Regional/ Country market analysis each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2031 for 5 regional and 16 key national markets – See forecasts for the Controlled Substance market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Argentina, Brazil, Germany, France, UK, Italy, Spain, China, India, Japan, and Australia among other prominent economies.
• Prospects for established firms and those seeking to enter the market– including company profiles for 15 of the major companies involved in the Controlled Substance Market. Some of the company’s profiled in this report include
• F. Hoffmann-La Roche AG
• AbbVie, Inc.
• Mallinckrodt plc
• Pfizer, Inc.
• Sun Pharmaceutical Ltd.
• Ampac Fine Chemicals
• GW Pharmaceuticals plc
• Merck & Co., Inc.
• Depomed, Inc.
• Coating Place, Inc.
• Corium International, Inc.
• Johnson and Johnson Services, Inc.
• Alkermes plc
• Pfizer, Inc.
• Orbis Biosciences, Inc.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Controlled Substance Market Report 2021-2031: Forecasts by Drug (Opioids, Stimulants, Depressants, and Cannabinoids), by Application (Attention-Deficit/Hyperactivity Disorder (ADHD), Pain Management, Depression, Sleep Disorder, Cough Suppression, Anxiety, Seizure, and Others), by Drug Type (Generic Drugs, and Branded Drugs), by Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), by End User (Hospitals, Homecare, Specialty Clinics, and Others), by Distribution Channel (Institutional Sale, and Retail Sales) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Controlled Substance Market
2.1. Controlled Substance Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Application Submarkets Definitions
3. Controlled Substance Market Overview
3.1. Global Controlled Substance Market Size and Forecast By Region
3.2. Global Controlled Substance Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of chronic pain
3.3.1.2. Growing demand for controlled substance in emerging economies
3.3.1.3. Surging investment in controlled substance
3.3.1.4. Increasing research and developed activates
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost of development
3.3.2.2. Stringent regulation associated with product development
3.3.3. Opportunities
3.3.3.1. Increasing strategic agreements in cholesterol lowering drugs market
3.3.3.2. Increasing research and development in controlled substance
3.3.4. Threads
3.3.4.1. Availability of the alternatives
3.3.4.2. Rapid change in logistics and transportation policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Controlled Substance Market Analysis and Forecast 2021-2031, By Drug (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Opioids
4.1.1.1. Opioids market size and forecast, 2021-2031 (USD Million)
4.1.2. Stimulants
4.1.2.1. Stimulants market size and forecast, 2021-2031 (USD Million)
4.1.3. Depressants
4.1.3.1. Depressants market size and forecast, 2021-2031 (USD Million)
4.1.4. Cannabinoids
4.1.4.1. Cannabinoids market size and forecast, 2021-2031 (USD Million)
5. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Attention-Deficit/Hyperactivity Disorder (ADHD)
5.1.1.1. Attention-Deficit/Hyperactivity Disorder (ADHD) Market size and forecast, 2021-2031 (USD Million)
5.1.2. Pain Management
5.1.2.1. Pain Management market size and forecast, 2021-2031 (USD Million)
5.1.3. Depression
5.1.3.1. Depression market size and forecast, 2021-2031 (USD Million)
5.1.4. Sleep Disorder
5.1.4.1. Sleep Disorder market size and forecast, 2021-2031 (USD Million)
5.1.5. Cough Suppression
5.1.5.1. Cough Suppression market size and forecast, 2021-2031 (USD Million)
5.1.6. Anxiety
5.1.6.1. Anxiety market size and forecast, 2021-2031 (USD Million)
5.1.7. Seizure
5.1.7.1. Seizure market size and forecast, 2021-2031 (USD Million)
5.1.8. Others
5.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Generic Drugs
6.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Branded Drugs
6.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Geriatric Patient
7.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
7.1.2. Adult Patient
7.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
7.1.3. Pediatric
7.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
8. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Institutional Sale
9.1.1.1. Institutional Sale market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Sales
9.1.2.1. Retail Sales market size and forecast, 2021-2031 (USD Million)
10. North America Controlled Substance Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Controlled Substance Market Size and Forecast By Drug
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Controlled Substance Market Size and Forecast By Application
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Controlled Substance Market Size and Forecast By Drug Type
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Controlled Substance Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Controlled Substance Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Controlled Substance Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Controlled Substance Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Controlled Substance Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Controlled Substance Market Size and Forecast By Drug
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Controlled Substance Market Size and Forecast By Application
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Controlled Substance Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Controlled Substance Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Controlled Substance Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Controlled Substance Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Controlled Substance Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Controlled Substance Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Controlled Substance Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Controlled Substance Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Controlled Substance Market Size and Forecast By Drug
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Controlled Substance Market Size and Forecast By Application
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Controlled Substance Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Controlled Substance Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Controlled Substance Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Controlled Substance Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Controlled Substance Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Controlled Substance Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Controlled Substance Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Controlled Substance Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Controlled Substance Market Size and Forecast By Drug
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Controlled Substance Market Size and Forecast By Application
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Controlled Substance Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Controlled Substance Market Size and Forecast By Patient Demographics
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Controlled Substance Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Controlled Substance Market Size and Forecast By Distribution Channel
13.8. Brazil Controlled Substance Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Controlled Substance Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Controlled Substance Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Controlled Substance Market Size and Forecast By Drug
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Controlled Substance Market Size and Forecast By Application
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Controlled Substance Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Controlled Substance Market Size and Forecast By Patient Demographics
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Controlled Substance Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Controlled Substance Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Controlled Substance Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Controlled Substance Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Controlled Substance Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Controlled Substance Market
15.1. F. Hoffmann-La Roche AG
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. AbbVie, Inc.
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Mallinckrodt plc
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Pfizer, Inc.
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. Sun Pharmaceutical Ltd.
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Ampac Fine Chemicals
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. GW Pharmaceuticals plc
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Merck & Co., Inc.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Depomed, Inc.
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Coating Place, Inc.
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Corium International, Inc.
15.11.1. Company Snapshot
15.11.2. Company Overview
15.11.3. Financial Performance (2015-2019)
15.11.3.1. Net Revenue
15.11.3.2. Gross Profit
15.11.3.3. Geographical Revenue, 2019
15.11.4. Product Offerings
15.11.5. Recent Initiatives (2017-2019)
15.12. Johnson and Johnson Services, Inc.
15.12.1. Company Snapshot
15.12.2. Company Overview
15.12.3. Financial Performance (2015-2019)
15.12.3.1. Net Revenue
15.12.3.2. Gross Profit
15.12.3.3. Geographical Revenue, 2019
15.12.4. Product Offerings
15.12.5. Recent Initiatives (2017-2019)
15.13. Alkermes plc
15.13.1. Company Snapshot
15.13.2. Company Overview
15.13.3. Financial Performance (2015-2019)
15.13.3.1. Net Revenue
15.13.3.2. Gross Profit
15.13.3.3. Geographical Revenue, 2019
15.13.4. Product Offerings
15.13.5. Recent Initiatives (2017-2019)
15.14. Orbis Biosciences, Inc.
15.14.1. Company Snapshot
15.14.2. Company Overview
15.14.3. Financial Performance (2015-2019)
15.14.3.1. Net Revenue
15.14.3.2. Gross Profit
15.14.3.3. Geographical Revenue, 2019
15.14.4. Product Offerings
15.14.5. Recent Initiatives (2017-2019)
15.15. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Controlled Substance Market Drivers & Restraints 2021
Table 7. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Rabbits h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 203. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Leading 14 Controlled Substance Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 402. F. Hoffmann-La Roche AGProfile 2019 (CEO, HQ, Founded, Website)
Table 403. F. Hoffmann-La Roche AG Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 404. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 405. AbbVie, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 406. Mallinckrodt plc Profile 2019 (CEO, HQ, Founded, Website)
Table 407. Heska Controlled Substance Product Offering (Segment, Product Offerings)
Table 408. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 409. Pfizer, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 410. Sun Pharmaceutical Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 411. Sun Pharmaceutical Ltd. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 412. Ampac Fine Chemicals Profile 2019 (CEO, HQ, Founded, Website)
Table 413. Ampac Fine Chemicals Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 414. GW Pharmaceuticals plc Profile 2019 (CEO, HQ, Founded, Website)
Table 415. GW Pharmaceuticals plc Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 416. Depomed, Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 417. Depomed, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 418. Coating Place, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 419. Coating Place, Inc. Controlled Substance Product Offering (Segment, Product Offerings)
Table 420. Corium International, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 421. Corium International, Inc.Controlled Substance Product Offering (Segment, Product Offerings)
Table 422. Johnson and Johnson Services, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 423. Johnson and Johnson Services, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 424. Alkermes plc Profile 2019 (CEO, HQ, Founded, Website)
Table 425. Alkermes plc . Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 426. Orbis Biosciences, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 427. Orbis Biosciences, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 428. Other Companies Involved in the Controlled Substance Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Controlled Substance Market Drivers & Restraints 2021
Figure 7. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Rabbits h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 203. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Porter’s Five Force Analysis
1.1. Introduction
1.2. Why You Should Read This Report
1.3. Key Questions Answered By This Analytical Report
1.4. Who is This Report For?
1.5. Methodology
1.6. Frequently Asked Questions (FAQ)
1.7. Associated Visiongain Reports
1.8. About Visiongain
2. Introduction to the Controlled Substance Market
2.1. Controlled Substance Market Definition
2.2. Application Submarkets Definitions
2.3. Component Submarkets Definitions
2.4. Application Submarkets Definitions
3. Controlled Substance Market Overview
3.1. Global Controlled Substance Market Size and Forecast By Region
3.2. Global Controlled Substance Market Share By Region
3.3. Market Dynamics
3.3.1. Market Drivers
3.3.1.1. Increasing prevalence of chronic pain
3.3.1.2. Growing demand for controlled substance in emerging economies
3.3.1.3. Surging investment in controlled substance
3.3.1.4. Increasing research and developed activates
3.3.2. Market Restraints/Challenges
3.3.2.1. High cost of development
3.3.2.2. Stringent regulation associated with product development
3.3.3. Opportunities
3.3.3.1. Increasing strategic agreements in cholesterol lowering drugs market
3.3.3.2. Increasing research and development in controlled substance
3.3.4. Threads
3.3.4.1. Availability of the alternatives
3.3.4.2. Rapid change in logistics and transportation policies
3.3.5. SWOT Analysis
3.3.5.1. Strengths
3.3.5.1.1. Strength 1
3.3.5.1.2. Strength 2
3.3.5.1.3. Strength 3
3.3.5.2. Weaknesses
3.3.5.2.1. Weakness 1
3.3.5.2.2. Weakness 2
3.3.5.2.3. Weakness 3
3.3.5.3. Opportunities
3.3.5.3.1. Opportunity 1
3.3.5.3.2. Opportunity 2
3.3.5.3.3. Opportunity 3
3.3.5.4. Threats
3.3.5.4.1. Threat 1
3.3.5.4.2. Threat 2
3.3.5.4.3. Threat 3
3.3.6. Porter’s Five Forces Analysis
3.3.6.1. Competitive Rivalry
3.3.6.2. Supplier Power
3.3.6.3. Buyer Power
3.3.6.4. Threat of Substitution
3.3.6.5. Threat of New Entry
4. Global Controlled Substance Market Analysis and Forecast 2021-2031, By Drug (Pre COVID and V, U, W and L COVID Recovery Scenarios)
4.1. Market Overview
4.1.1. Opioids
4.1.1.1. Opioids market size and forecast, 2021-2031 (USD Million)
4.1.2. Stimulants
4.1.2.1. Stimulants market size and forecast, 2021-2031 (USD Million)
4.1.3. Depressants
4.1.3.1. Depressants market size and forecast, 2021-2031 (USD Million)
4.1.4. Cannabinoids
4.1.4.1. Cannabinoids market size and forecast, 2021-2031 (USD Million)
5. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Application (Pre COVID and V, U, W and L COVID Recovery Scenarios)
5.1. Market Overview
5.1.1. Attention-Deficit/Hyperactivity Disorder (ADHD)
5.1.1.1. Attention-Deficit/Hyperactivity Disorder (ADHD) Market size and forecast, 2021-2031 (USD Million)
5.1.2. Pain Management
5.1.2.1. Pain Management market size and forecast, 2021-2031 (USD Million)
5.1.3. Depression
5.1.3.1. Depression market size and forecast, 2021-2031 (USD Million)
5.1.4. Sleep Disorder
5.1.4.1. Sleep Disorder market size and forecast, 2021-2031 (USD Million)
5.1.5. Cough Suppression
5.1.5.1. Cough Suppression market size and forecast, 2021-2031 (USD Million)
5.1.6. Anxiety
5.1.6.1. Anxiety market size and forecast, 2021-2031 (USD Million)
5.1.7. Seizure
5.1.7.1. Seizure market size and forecast, 2021-2031 (USD Million)
5.1.8. Others
5.1.8.1. Others market size and forecast, 2021-2031 (USD Million)
6. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Drug Type (Pre COVID and V, U, W and L COVID Recovery Scenarios)
6.1. Market Overview
6.1.1. Generic Drugs
6.1.1.1. Generic Drugs market size and forecast, 2021-2031 (USD Million)
6.1.2. Branded Drugs
6.1.2.1. Branded Drugs market size and forecast, 2021-2031 (USD Million)
7. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Patient Demographics (Pre COVID and V, U, W and L COVID Recovery Scenarios)
7.1. Market Overview
7.1.1. Geriatric Patient
7.1.1.1. Geriatric Patient market size and forecast, 2021-2031 (USD Million)
7.1.2. Adult Patient
7.1.2.1. Adult Patient market size and forecast, 2021-2031 (USD Million)
7.1.3. Pediatric
7.1.3.1. Pediatric market size and forecast, 2021-2031 (USD Million)
8. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By End-User (Pre COVID and V, U, W and L COVID Recovery Scenarios)
8.1. Market Overview
8.1.1. Hospitals
8.1.1.1. Hospitals market size and forecast, 2021-2031 (USD Million)
8.1.2. Homecare
8.1.2.1. Homecare market size and forecast, 2021-2031 (USD Million)
8.1.3. Specialty Clinics
8.1.3.1. Specialty Clinics market size and forecast, 2021-2031 (USD Million)
8.1.4. Others
8.1.4.1. Others market size and forecast, 2021-2031 (USD Million)
9. Global Controlled Substance Market Analysis and Forecast, 2021-2031 By Distribution Channel (Pre COVID and V, U, W and L COVID Recovery Scenarios)
9.1. Market Overview
9.1.1. Institutional Sale
9.1.1.1. Institutional Sale market size and forecast, 2021-2031 (USD Million)
9.1.2. Retail Sales
9.1.2.1. Retail Sales market size and forecast, 2021-2031 (USD Million)
10. North America Controlled Substance Market Analysis and Forecast, 2021-2031 Pre COVID and V, U, W and L COVID Recovery Scenarios)
10.1. Market Overview
10.2. North America Controlled Substance Market Size and Forecast By Drug
10.2.1.1. XX Driving/Opportunity Factor
10.2.1.2. XX Driving/Opportunity Factor
10.3. North America Controlled Substance Market Size and Forecast By Application
10.3.1.1. XX Driving/Opportunity Factor
10.3.1.2. XX Driving/Opportunity Factor
10.4. North America Controlled Substance Market Size and Forecast By Drug Type
10.4.1.1. XX Driving/Opportunity Factor
10.4.1.2. XX Driving/Opportunity Factor
10.5. North America Controlled Substance Market Size and Forecast By Patient Demographics
10.5.1.1. XX Driving/Opportunity Factor
10.5.1.2. XX Driving/Opportunity Factor
10.6. North America Controlled Substance Market Size and Forecast By End-User
10.6.1.1. XX Driving/Opportunity Factor
10.6.1.2. XX Driving/Opportunity Factor
10.7. North America Controlled Substance Market Size and Forecast By Distribution Channel
10.7.1.1. XX Driving/Opportunity Factor
10.7.1.2. XX Driving/Opportunity Factor
10.8. U.S. Controlled Substance Market
10.8.1.1. XX Driving/Opportunity Factor
10.8.1.2. XX Driving/Opportunity Factor
10.9. Canada Controlled Substance Market
10.9.1.1. XX Driving/Opportunity Factor
10.9.1.2. XX Driving/Opportunity Factor
11. Europe Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
11.1. Market Overview
11.2. Europe Controlled Substance Market Size and Forecast By Drug
11.2.1.1. XX Driving/Opportunity Factor
11.2.1.2. XX Driving/Opportunity Factor
11.3. Europe Controlled Substance Market Size and Forecast By Application
11.3.1.1. XX Driving/Opportunity Factor
11.3.1.2. XX Driving/Opportunity Factor
11.4. Europe Controlled Substance Market Size and Forecast By Drug Type
11.4.1.1. XX Driving/Opportunity Factor
11.4.1.2. XX Driving/Opportunity Factor
11.5. Europe Controlled Substance Market Size and Forecast By Patient Demographics
11.5.1.1. XX Driving/Opportunity Factor
11.5.1.2. XX Driving/Opportunity Factor
11.6. Europe Controlled Substance Market Size and Forecast By End-User
11.6.1.1. XX Driving/Opportunity Factor
11.6.1.2. XX Driving/Opportunity Factor
11.7. Europe Controlled Substance Market Size and Forecast By Distribution Channel
11.7.1.1. XX Driving/Opportunity Factor
11.7.1.2. XX Driving/Opportunity Factor
11.8. UK Controlled Substance Market
11.8.1.1. XX Driving/Opportunity Factor
11.8.1.2. XX Driving/Opportunity Factor
11.9. Germany Controlled Substance Market
11.9.1.1. XX Driving/Opportunity Factor
11.9.1.2. XX Driving/Opportunity Factor
11.10. France Controlled Substance Market
11.10.1.1. XX Driving/Opportunity Factor
11.10.1.2. XX Driving/Opportunity Factor
11.11. Rest of Europe Controlled Substance Market
11.11.1.1. XX Driving/Opportunity Factor
11.11.1.2. XX Driving/Opportunity Factor
12. Asia Pacific Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
12.1. Market Overview
12.2. Asia-Pacific Controlled Substance Market Size and Forecast By Drug
12.2.1.1. XX Driving/Opportunity Factor
12.2.1.2. XX Driving/Opportunity Factor
12.3. Asia-Pacific Controlled Substance Market Size and Forecast By Application
12.3.1.1. XX Driving/Opportunity Factor
12.3.1.2. XX Driving/Opportunity Factor
12.4. Asia-Pacific Controlled Substance Market Size and Forecast By Drug Type
12.4.1.1. XX Driving/Opportunity Factor
12.4.1.2. XX Driving/Opportunity Factor
12.5. Asia-Pacific Controlled Substance Market Size and Forecast By Patient Demographics
12.5.1.1. XX Driving/Opportunity Factor
12.5.1.2. XX Driving/Opportunity Factor
12.6. Asia-Pacific Controlled Substance Market Size and Forecast By End-User
12.6.1.1. XX Driving/Opportunity Factor
12.6.1.2. XX Driving/Opportunity Factor
12.7. Asia-Pacific Controlled Substance Market Size and Forecast By Distribution Channel
12.7.1.1. XX Driving/Opportunity Factor
12.7.1.2. XX Driving/Opportunity Factor
12.8. China Controlled Substance Market
12.8.1.1. XX Driving/Opportunity Factor
12.8.1.2. XX Driving/Opportunity Factor
12.9. India Controlled Substance Market
12.9.1.1. XX Driving/Opportunity Factor
12.9.1.2. XX Driving/Opportunity Factor
12.10. Japan Controlled Substance Market
12.10.1.1. XX Driving/Opportunity Factor
12.10.1.2. XX Driving/Opportunity Factor
12.11. Rest of Asia Pacific Controlled Substance Market
12.11.1.1. XX Driving/Opportunity Factor
12.11.1.2. XX Driving/Opportunity Factor
13. Latin America Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
13.1. Market Overview
13.2. Latin America Controlled Substance Market Size and Forecast By Drug
13.2.1.1. XX Driving/Opportunity Factor
13.2.1.2. XX Driving/Opportunity Factor
13.3. Latin America Controlled Substance Market Size and Forecast By Application
13.3.1.1. XX Driving/Opportunity Factor
13.3.1.2. XX Driving/Opportunity Factor
13.4. Latin America Controlled Substance Market Size and Forecast By Drug Type
13.4.1.1. XX Driving/Opportunity Factor
13.4.1.2. XX Driving/Opportunity Factor
13.5. Latin America Controlled Substance Market Size and Forecast By Patient Demographics
13.5.1.1. XX Driving/Opportunity Factor
13.5.1.2. XX Driving/Opportunity Factor
13.6. Latin America Controlled Substance Market Size and Forecast By End-User
13.6.1.1. XX Driving/Opportunity Factor
13.6.1.2. XX Driving/Opportunity Factor
13.7. Latin America Controlled Substance Market Size and Forecast By Distribution Channel
13.8. Brazil Controlled Substance Market
13.8.1.1. XX Driving/Opportunity Factor
13.8.1.2. XX Driving/Opportunity Factor
13.9. Mexico Controlled Substance Market
13.9.1.1. XX Driving/Opportunity Factor
13.9.1.2. XX Driving/Opportunity Factor
13.10. Rest of Latin America Controlled Substance Market
13.10.1.1. XX Driving/Opportunity Factor
13.10.1.2. XX Driving/Opportunity Factor
14. MEA Controlled Substance Market Analysis and Forecast, 2021-2031 (Pre COVID and V, U, W and L COVID Recovery Scenarios)
14.1. Market Overview
14.2. MEA Controlled Substance Market Size and Forecast By Drug
14.2.1.1. XX Driving/Opportunity Factor
14.2.1.2. XX Driving/Opportunity Factor
14.3. MEA Controlled Substance Market Size and Forecast By Application
14.3.1.1. XX Driving/Opportunity Factor
14.3.1.2. XX Driving/Opportunity Factor
14.4. MEA Controlled Substance Market Size and Forecast By Drug Type
14.4.1.1. XX Driving/Opportunity Factor
14.4.1.2. XX Driving/Opportunity Factor
14.5. MEA Controlled Substance Market Size and Forecast By Patient Demographics
14.5.1.1. XX Driving/Opportunity Factor
14.5.1.2. XX Driving/Opportunity Factor
14.6. MEA Controlled Substance Market Size and Forecast By End-User
14.6.1.1. XX Driving/Opportunity Factor
14.6.1.2. XX Driving/Opportunity Factor
14.7. MEA Controlled Substance Market Size and Forecast By Distribution Channel
14.7.1.1. XX Driving/Opportunity Factor
14.7.1.2. XX Driving/Opportunity Factor
14.8. GCC Controlled Substance Market
14.8.1.1. XX Driving/Opportunity Factor
14.8.1.2. XX Driving/Opportunity Factor
14.9. South Africa Controlled Substance Market
14.9.1.1. XX Driving/Opportunity Factor
14.9.1.2. XX Driving/Opportunity Factor
14.10. Rest of MEA Controlled Substance Market
14.10.1.1. XX Driving/Opportunity Factor
14.10.1.2. XX Driving/Opportunity Factor
15. Companies in the Controlled Substance Market
15.1. F. Hoffmann-La Roche AG
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Performance (2015-2019)
15.1.3.1. Net Revenue
15.1.3.2. Gross Profit
15.1.3.3. Geographical Revenue, 2019
15.1.4. Product Offerings
15.1.5. Recent Initiatives (2017-2019)
15.2. AbbVie, Inc.
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Performance (2015-2019)
15.2.3.1. Net Revenue
15.2.3.2. Gross Profit
15.2.3.3. Geographical Revenue, 2019
15.2.4. Product Offerings
15.2.5. Recent Initiatives (2017-2019)
15.3. Mallinckrodt plc
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Performance (2015-2019)
15.3.3.1. Net Revenue
15.3.3.2. Gross Profit
15.3.3.3. Geographical Revenue, 2019
15.3.4. Product Offerings
15.3.5. Recent Initiatives (2017-2019)
15.4. Pfizer, Inc.
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Performance (2015-2019)
15.4.3.1. Net Revenue
15.4.3.2. Gross Profit
15.4.3.3. Geographical Revenue, 2019
15.4.4. Product Offerings
15.4.5. Recent Initiatives (2017-2019)
15.5. Sun Pharmaceutical Ltd.
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Performance (2015-2019)
15.5.3.1. Net Revenue
15.5.3.2. Gross Profit
15.5.3.3. Geographical Revenue, 2019
15.5.4. Product Offerings
15.5.5. Recent Initiatives (2017-2019)
15.6. Ampac Fine Chemicals
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Performance (2015-2019)
15.6.3.1. Net Revenue
15.6.3.2. Gross Profit
15.6.3.3. Geographical Revenue, 2019
15.6.4. Product Offerings
15.6.5. Recent Initiatives (2017-2019)
15.7. GW Pharmaceuticals plc
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Performance (2015-2019)
15.7.3.1. Net Revenue
15.7.3.2. Gross Profit
15.7.3.3. Geographical Revenue, 2019
15.7.4. Product Offerings
15.7.5. Recent Initiatives (2017-2019)
15.8. Merck & Co., Inc.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Performance (2015-2019)
15.8.3.1. Net Revenue
15.8.3.2. Gross Profit
15.8.3.3. Geographical Revenue, 2019
15.8.4. Product Offerings
15.8.5. Recent Initiatives (2017-2019)
15.9. Depomed, Inc.
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Performance (2015-2019)
15.9.3.1. Net Revenue
15.9.3.2. Gross Profit
15.9.3.3. Geographical Revenue, 2019
15.9.4. Product Offerings
15.9.5. Recent Initiatives (2017-2019)
15.10. Coating Place, Inc.
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Performance (2015-2019)
15.10.3.1. Net Revenue
15.10.3.2. Gross Profit
15.10.3.3. Geographical Revenue, 2019
15.10.4. Product Offerings
15.10.5. Recent Initiatives (2017-2019)
15.11. Corium International, Inc.
15.11.1. Company Snapshot
15.11.2. Company Overview
15.11.3. Financial Performance (2015-2019)
15.11.3.1. Net Revenue
15.11.3.2. Gross Profit
15.11.3.3. Geographical Revenue, 2019
15.11.4. Product Offerings
15.11.5. Recent Initiatives (2017-2019)
15.12. Johnson and Johnson Services, Inc.
15.12.1. Company Snapshot
15.12.2. Company Overview
15.12.3. Financial Performance (2015-2019)
15.12.3.1. Net Revenue
15.12.3.2. Gross Profit
15.12.3.3. Geographical Revenue, 2019
15.12.4. Product Offerings
15.12.5. Recent Initiatives (2017-2019)
15.13. Alkermes plc
15.13.1. Company Snapshot
15.13.2. Company Overview
15.13.3. Financial Performance (2015-2019)
15.13.3.1. Net Revenue
15.13.3.2. Gross Profit
15.13.3.3. Geographical Revenue, 2019
15.13.4. Product Offerings
15.13.5. Recent Initiatives (2017-2019)
15.14. Orbis Biosciences, Inc.
15.14.1. Company Snapshot
15.14.2. Company Overview
15.14.3. Financial Performance (2015-2019)
15.14.3.1. Net Revenue
15.14.3.2. Gross Profit
15.14.3.3. Geographical Revenue, 2019
15.14.4. Product Offerings
15.14.5. Recent Initiatives (2017-2019)
15.15. Other Notable Players
16. Conclusion
17. Glossary
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain report evaluation form
LIST OF TABLES
Table 1. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 2. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 3. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 4. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 5. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 6. Controlled Substance Market Drivers & Restraints 2021
Table 7. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 8. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 9. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 10. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 11. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 12. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 13. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 14. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 15. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 16. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 17. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 18. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 19. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 20. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 21. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 22. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 23. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 24. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 25. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 26. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 27. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 28. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 29. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 30. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 31. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 32. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 33. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 34. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 35. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 36. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 37. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 38. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 39. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 40. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 41. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 42. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 43. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 44. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 45. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 46. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 47. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 48. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 49. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 50. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 51. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 52. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 53. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 54. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 55. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 56. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 57. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 58. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 59. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 60. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 61. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 62. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 63. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 64. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 65. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 66. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 67. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 68. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 69. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 70. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 71. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 77. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 78. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 79. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 80. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 81. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 82. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 83. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 84. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 85. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 86. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 87. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 88. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 89. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 90. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 91. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 92. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 93. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 94. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 95. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 96. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 97. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 98. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 99. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 100. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 101. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 102. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 103. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 104. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 105. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 106. Rabbits h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 117. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 118. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 119. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 120. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 121. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 122. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 123. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 124. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 125. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 127. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 128. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 129. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 130. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 132. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 133. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 134. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 135. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 137. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 138. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 139. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 140. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 142. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 143. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 144. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 145. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 146. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 147. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 148. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 149. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 150. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 151. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 152. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Table 153. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Table 154. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Table 155. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Table 156. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Table 157. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 158. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 159. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 160. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 161. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 162. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 163. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 164. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 165. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 166. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 167. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 168. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 169. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 170. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 171. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 172. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 173. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 174. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 175. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 176. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 177. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 178. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 179. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 180. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 181. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 182. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 183. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 184. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 185. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 186. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 187. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 188. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 189. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 190. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 191. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 192. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 193. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 194. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 195. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 196. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 197. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 198. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 199. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 200. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 201. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 202. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Table 203. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 204. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 205. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 206. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 207. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 208. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 209. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 210. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 211. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 212. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 213. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 214. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 215. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 216. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 217. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 218. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 219. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 220. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 221. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 222. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 223. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 224. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 225. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 226. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 227. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 228. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 229. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 230. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 231. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 232. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 233. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 234. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 235. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 236. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 237. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 238. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 239. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 240. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 241. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 242. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 243. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 244. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 245. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 246. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 247. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 248. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 249. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 250. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 251. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 252. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 253. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 254. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 255. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 256. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 257. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 258. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 259. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 260. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 261. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 262. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 263. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 264. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 265. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 266. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 267. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 268. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 269. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 270. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 271. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 272. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 273. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 274. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 275. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 276. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 277. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 278. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 279. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 280. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 281. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 282. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 283. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 284. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 285. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 286. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 287. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 288. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 289. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 290. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 291. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 292. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 293. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 294. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 295. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 296. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 297. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 298. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 299. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 300. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 301. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 302. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 303. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 304. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 305. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 306. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 307. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 308. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 309. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 310. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 311. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 312. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 313. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 314. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 315. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 316. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 317. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 318. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 319. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 320. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 321. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 322. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 323. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 324. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 325. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 326. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 327. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 328. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 329. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 330. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 331. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 332. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 333. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 334. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 335. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 336. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 337. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 338. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 339. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 340. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 341. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 342. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 343. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 344. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 345. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 346. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 347. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 348. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 349. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 350. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 351. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 352. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 353. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 354. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 355. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 356. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 357. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 358. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 359. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 360. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 361. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 362. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 363. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 364. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 365. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 366. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 367. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 368. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 369. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 370. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 371. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 372. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 373. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 374. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 375. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 376. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 377. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 378. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 379. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 380. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 381. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 382. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 383. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 384. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 385. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 386. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 387. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 388. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 389. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 390. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 391. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 392. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 393. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 394. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 395. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 396. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Table 397. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Table 398. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Table 399. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Table 400. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Table 401. Leading 14 Controlled Substance Companies (Ranking, Company, Latest Total Company Sales US$M*, HQ)
Table 402. F. Hoffmann-La Roche AGProfile 2019 (CEO, HQ, Founded, Website)
Table 403. F. Hoffmann-La Roche AG Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 404. AbbVie, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 405. AbbVie, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 406. Mallinckrodt plc Profile 2019 (CEO, HQ, Founded, Website)
Table 407. Heska Controlled Substance Product Offering (Segment, Product Offerings)
Table 408. Pfizer, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 409. Pfizer, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 410. Sun Pharmaceutical Ltd. Profile 2019 (CEO, HQ, Founded, Website)
Table 411. Sun Pharmaceutical Ltd. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 412. Ampac Fine Chemicals Profile 2019 (CEO, HQ, Founded, Website)
Table 413. Ampac Fine Chemicals Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 414. GW Pharmaceuticals plc Profile 2019 (CEO, HQ, Founded, Website)
Table 415. GW Pharmaceuticals plc Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 416. Depomed, Inc.Profile 2019 (CEO, HQ, Founded, Website)
Table 417. Depomed, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 418. Coating Place, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 419. Coating Place, Inc. Controlled Substance Product Offering (Segment, Product Offerings)
Table 420. Corium International, Inc.Corporation Profile 2019 (CEO, HQ, Founded, Website)
Table 421. Corium International, Inc.Controlled Substance Product Offering (Segment, Product Offerings)
Table 422. Johnson and Johnson Services, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 423. Johnson and Johnson Services, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 424. Alkermes plc Profile 2019 (CEO, HQ, Founded, Website)
Table 425. Alkermes plc . Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 426. Orbis Biosciences, Inc. Profile 2019 (CEO, HQ, Founded, Website)
Table 427. Orbis Biosciences, Inc. Animal Diagnostics Product Offering (Segment, Product Offerings)
Table 428. Other Companies Involved in the Controlled Substance Market 2021 (Company, Location)
LIST OF FIGURES
Figure 1. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 2. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 3. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 4. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 5. Controlled Substance Market Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 6. Controlled Substance Market Drivers & Restraints 2021
Figure 7. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 8. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 9. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 10. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 11. Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 12. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 13. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 14. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 15. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 16. Opioids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 17. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 18. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 19. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 20. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 21. Stimulants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 22. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 23. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 24. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 25. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 26. Depressants Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 27. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 28. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 29. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 30. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 31. Cannabinoids Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 32. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 33. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 34. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 35. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 36. Controlled Substance Market Forecast By Application 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 37. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 38. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 39. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 40. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 41. Attention-Deficit/Hyperactivity Disorder (ADHD) Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 42. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 43. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 44. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 45. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 46. Pain Management Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 47. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 48. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 49. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 50. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 51. Depression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 52. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 53. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 54. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 55. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 56. Sleep Disorder Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 57. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 58. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 59. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 60. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 61. Cough Suppression Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 62. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 63. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 64. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 65. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 66. Anxiety Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 67. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 68. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 69. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 70. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 71. Seizure Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 72. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 73. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 74. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 75. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 76. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 77. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 78. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 79. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 80. Controlled Substance Market Forecast By Drug Type Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 81. Controlled Substance Market Forecast By Drug Type 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 82. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 83. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 84. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 85. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 86. Generic Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 87. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 88. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 89. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 90. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 91. Branded Drugs Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 92. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 93. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 94. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 95. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 96. Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 97. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 98. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 99. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 100. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 101. Geriatric Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 102. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 103. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 104. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 105. Rabbits Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 106. Rabbits h Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 107. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 108. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 109. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 110. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 111. Adult Patient Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 112. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 113. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 114. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 115. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 116. Pediatric Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 117. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 118. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 119. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 120. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 121. Controlled Substance Market Forecast By End-User 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 122. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 123. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 124. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 125. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 126. Hospitals Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 127. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 128. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 129. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 130. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 131. Homecare Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 132. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 133. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 134. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 135. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 136. Specialty Clinics Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 137. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 138. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 139. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 140. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 141. Others Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 142. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 143. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 144. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 145. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 146. Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 147. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 148. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 149. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 150. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 151. Institutional Sale Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 152. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (Before COVID)
Figure 153. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario V)
Figure 154. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario U)
Figure 155. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario W)
Figure 156. Retail Sales Forecast 2021-2031 (US$Mn, AGR %, CAGR %) (COVID - Scenario L)
Figure 157. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 158. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 159. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 160. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 161. North America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 162. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 163. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 164. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 165. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 166. North America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 167. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 168. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 169. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 170. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 171. North America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 172. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 173. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 174. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 175. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 176. North America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 177. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 178. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 179. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 180. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 181. North America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 182. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 183. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 184. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 185. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 186. North America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 187. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 188. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 189. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 190. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 191. North America Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 192. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 193. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 194. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 195. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 196. US Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 197. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 198. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 199. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 200. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 201. Canada Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 202. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID) Table 82.
Figure 203. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 204. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 205. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 206. Europe Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 207. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 208. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 209. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 210. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 211. Europe Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 212. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 213. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 214. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 215. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 216. Europe Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 217. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 218. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 219. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 220. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 221. Europe Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 222. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 223. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 224. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 225. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 226. Europe Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 227. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 228. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 229. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 230. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 231. Europe Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 232. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 233. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 234. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 235. Europe Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 236. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 237. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 238. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 239. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 240. UK Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 241. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 242. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 243. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 244. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 245. Germany Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 246. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 247. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 248. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 249. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 250. France Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 251. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 252. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 253. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 254. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 255. Rest of Europe Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 256. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 257. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 258. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 259. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 260. Asia Pacific Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 261. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 262. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 263. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 264. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 265. Asia Pacific Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 266. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 267. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 268. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 269. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 270. Asia Pacific Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 271. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 272. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 273. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 274. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 275. Asia Pacific Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 276. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 277. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 278. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 279. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 280. Asia Pacific Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 281. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 282. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 283. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 284. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 285. Asia Pacific Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 286. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 287. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 288. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 289. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 290. Asia Pacific Controlled Substance Market Forecast By Country 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 291. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 292. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 293. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 294. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 295. China Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 296. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 297. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 298. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 299. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 300. India Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 301. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 302. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 303. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 304. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 305. Japan Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 306. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 307. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 308. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 309. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 310. RoAPAC Controlled Substance Market Forecast 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 311. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 312. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 313. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 314. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 315. Middle East Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 316. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 317. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 318. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 319. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 320. Middle East Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 321. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 322. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 323. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 324. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 325. Middle East Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 326. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 327. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 328. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 329. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 330. Middle East Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 331. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 332. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 333. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 334. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 335. Middle East Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 336. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 337. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 338. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 339. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 340. Middle East Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 341. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 342. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 343. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 344. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 345. Latin America Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 346. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 347. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 348. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 349. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 350. Latin America Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 351. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 352. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 353. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 354. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 355. Latin America Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 356. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 357. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 358. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 359. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 360. Latin America Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 361. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 362. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 363. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 364. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 365. Latin America Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 366. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 367. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 368. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 369. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 370. Latin America Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 371. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 372. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 373. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 374. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 375. Africa Controlled Substance Market Forecast By Drug 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 376. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 377. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 378. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 379. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 380. Africa Controlled Substance Market Forecast By Application 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 381. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 382. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 383. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 384. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 385. Africa Controlled Substance Market Forecast By Drug Type 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 386. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 387. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 388. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 389. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 390. Africa Controlled Substance Market Forecast By Patient Demographics 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 391. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 392. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 393. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 394. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 395. Africa Controlled Substance Market Forecast By End-User 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 396. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (Before COVID)
Figure 397. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario V)
Figure 398. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario U)
Figure 399. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario W)
Figure 400. Africa Controlled Substance Market Forecast By Distribution Channel 2021-2031 (US$M, AGR %, CAGR %) (COVID - Scenario L)
Figure 401. Porter’s Five Force Analysis
Companies Profiled in the Report
1. F. Hoffmann-La Roche AG
2. AbbVie, Inc.
3. Mallinckrodt plc
4. Pfizer, Inc.
5. Sun Pharmaceutical Ltd.
6. Ampac Fine Chemicals
7. GW Pharmaceuticals plc
8. Merck & Co., Inc.
9. Depomed, Inc.
10. Coating Place, Inc.
11. Corium International, Inc.
12. Johnson and Johnson Services, Inc.
13. Alkermes plc
14. Pfizer, Inc.
15. Orbis Biosciences, Inc.
List of Companies Mentioned in the Report:
1. BD
2. Illumina, Inc.
3. Nova Biomedical
4. Abbott
5. AbbVie Inc.
6. ACON Laboratories Inc.
7. AdvaCare Pharma
8. ARKRAY USA, Inc.
9. Atomo Diagnostics
10. Avecon Healthcare Pvt Ltd
11. Beckman Coulter, Inc. ( a subsidiary of Danaher)
12. Biohit Oyj
13. bioLytical Laboratories Inc.
14. BIOMEDOMICS INC
15. bioMérieux SA
16. Bio-Rad Laboratories, Inc.
17. BODITECH MED INC.
18. Chembio Diagnostic Systems, Inc.
19. Chembio Diagnostic Systems, Inc.
20. Chembio Diagnostic Systems, Inc.
21. Diagenode Diagnostics
22. Diagnosis S.A.
23. DiaSorin S.p.A.
24. EKF Diagnostics Holdings plc
25. F. Hoffmann-La Roche Ltd
26. Germaine Laboratories, Inc.
27. Gilead Sciences, Inc.
28. Gilead Sciences, Inc.
29. Grifols, S.A
30. Hemosure, Inc.
31. Hologic, Inc.
32. HUMASIS.
33. Janssen Global Services, LLC
34. Johnson & Johnson Services, Inc.
35. Lamdagen Corporation
36. LifeSign LLC.
37. Maccura Biotechnology Co., Ltd.
38. Medixbiochemica
39. Merck & Co., Inc.
40. Merck KGaA
41. MicroGen Diagnostics
42. Mylan N.V.
43. Nanoentek
44. Nanoentek
45. OraSure Technologies, Inc.
46. PerkinElmer Inc.
47. PointCare
48. QIAGEN
49. Quidel Corporation
50. Sannuo Biosensing Co., Ltd.
51. Siemens Healthcare GmbH
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
1. F. Hoffmann-La Roche AG
2. AbbVie, Inc.
3. Mallinckrodt plc
4. Pfizer, Inc.
5. Sun Pharmaceutical Ltd.
6. Ampac Fine Chemicals
7. GW Pharmaceuticals plc
8. Merck & Co., Inc.
9. Depomed, Inc.
10. Coating Place, Inc.
11. Corium International, Inc.
12. Johnson and Johnson Services, Inc.
13. Alkermes plc
14. Pfizer, Inc.
15. Orbis Biosciences, Inc.
List of Companies Mentioned in the Report:
1. BD
2. Illumina, Inc.
3. Nova Biomedical
4. Abbott
5. AbbVie Inc.
6. ACON Laboratories Inc.
7. AdvaCare Pharma
8. ARKRAY USA, Inc.
9. Atomo Diagnostics
10. Avecon Healthcare Pvt Ltd
11. Beckman Coulter, Inc. ( a subsidiary of Danaher)
12. Biohit Oyj
13. bioLytical Laboratories Inc.
14. BIOMEDOMICS INC
15. bioMérieux SA
16. Bio-Rad Laboratories, Inc.
17. BODITECH MED INC.
18. Chembio Diagnostic Systems, Inc.
19. Chembio Diagnostic Systems, Inc.
20. Chembio Diagnostic Systems, Inc.
21. Diagenode Diagnostics
22. Diagnosis S.A.
23. DiaSorin S.p.A.
24. EKF Diagnostics Holdings plc
25. F. Hoffmann-La Roche Ltd
26. Germaine Laboratories, Inc.
27. Gilead Sciences, Inc.
28. Gilead Sciences, Inc.
29. Grifols, S.A
30. Hemosure, Inc.
31. Hologic, Inc.
32. HUMASIS.
33. Janssen Global Services, LLC
34. Johnson & Johnson Services, Inc.
35. Lamdagen Corporation
36. LifeSign LLC.
37. Maccura Biotechnology Co., Ltd.
38. Medixbiochemica
39. Merck & Co., Inc.
40. Merck KGaA
41. MicroGen Diagnostics
42. Mylan N.V.
43. Nanoentek
44. Nanoentek
45. OraSure Technologies, Inc.
46. PerkinElmer Inc.
47. PointCare
48. QIAGEN
49. Quidel Corporation
50. Sannuo Biosensing Co., Ltd.
51. Siemens Healthcare GmbH
List of Organizations Mentioned in the Report:
1. Agência Nacional de Vigilância Sanitária (ANVISA)
2. Duke University
3. European Medicines Agency (EMA)
4. Food and Drug Administration (FDA)
5. Ministry of Health, Labour and Welfare (MHLW)
6. Michigan State University
7. National Institute for Health and Clinical Excellence (NICE)
8. National Institutes of Health (NIH)
9. University of Connecticut
10. World Health Organization (WHO)
11. The National Medical Products Administration (NMPA)
12. Indian Council of Medical Research (ICMR)
13. The Therapeutic Goods Administration
14. The Federal Institute for Drugs and Medical Devices (BfArM)
15. Pharmaceuticals and Medical Devices Agency (PMDA)
16. Agencia Nacional de Vigiloncia Sanitaria (ANVISA )
17. Ministry of Health, Labour & Welfare(MHLW)
18. Medicines and Healthcare Products Regulatory Agency (MHRA)
19. Centre for Pharmaceutical Administration Health Sciences Authority
20. Central Drug Standard Control Organization (CDSCO)
Download sample pages
Complete the form below to download your free sample pages for Controlled Substance Market Report 2021-2031Related reports
-
Virus Testing Diagnostic Kits Market Report 2021-2031
With the growing burden of rare diseases around the world, there has been a rise in the requirement for proper...Full DetailsPublished: 25 November 2020 -
Next-Generation Pharmaceutical Temperature Management Solutions Market Report 2020-2030
Maintaining the quality and safety of the product in the supply chain has always been a high priority for pharmaceutical...Full DetailsPublished: 25 September 2020 -
Plasma Therapy Market Report 2021-2031
The market is forecasted for the next ten years based on market growth within each segment of the blood plasma...Full DetailsPublished: 16 November 2020 -
Cholesterol Lowering Drugs Market Report 2021-2031
Increasing risk of high cholesterol and associated diseases has lead various leading drug manufactures to increase their research and development...Full DetailsPublished: 01 January 1970 -
Track and Trace Solutions Market Report 2021-2031
The key factors driving the growth of this market include the severe regulations & principles for the implementation of serialization,...
Full DetailsPublished: 01 January 1970 -
Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031
Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing...Full DetailsPublished: 24 November 2020 -
Drugs of Abuse Testing Market Report 2021-2031
Drugs Abuse has risen very significantly in few last year as compared to previous once and expected to continuously rise...Full DetailsPublished: 01 January 1970 -
ePharmacy Market Report 2021-2031
The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and...Full DetailsPublished: 19 April 2021 -
Cold Laser Therapy Market Report 2021-2031
Prevalence of chronic and non-chronic diseases is increasing significantly due to rapidly changing lifestyle and increased consumption of malnutrition and...
Full DetailsPublished: 01 January 1970 -
Biobanking Market Report 2021-2031
In clinical trials relating to COVID-19, COVID-19 biobanks will play an important role. These biobanks will play an instrumental role...Full DetailsPublished: 21 October 2020
Download sample pages
Complete the form below to download your free sample pages for Controlled Substance Market Report 2021-2031Do you have any custom requirements we can help you with?
Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: jamie.roberts@visiongain.com
Would you like a free report overview of the report of your choice?
If so, please drop an email to Jamie Roberts stating your chosen report title to jamie.roberts@visiongain.com
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email jamie.roberts@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034
The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.
18 April 2024
Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034
The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.
17 April 2024
Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034
The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.
12 April 2024
Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034
The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.
11 April 2024
